Kaleido Biosciences

Kaleido Biosciences

A biotechnology company making discoveries in genetic and metabolic diversity of the human microbiome into treatment and therapies for a wide range of diseases.

Kaleido Biosciences is a biotechnology company making discoveries in genetic and metabolic diversity of the human microbiome into treatment and therapies for a wide range of diseases that is headquartered in Bedford, Massachusetts and was founded in 2015 by Geoffrey von Maltzahn and Noubar Afeyan.

Funding

Venture

On September 17, 2017 Kaleido Biosciences completed a venture capital round that brought thier total amount of funding to date to $65 million. The round was led by Flagship Pioneering (lead investor and a number of institutional and individual investors which included Mike Bonney. At the time of announcing their venture funding the company also announced that Mike Bonney will be joining the Kaleido management team and board of directors.

Series C

On June 25, 2018 Kaleido Biosciences announced completing their oversubscribed series C funding round with $101 million in funding from Abu Dhabi Investment Authority (ADIA), Fidelity Management and Research Company, Invus, and Rock Springs Capital, Flagship Pioneering, and several undisclosed investors. The company plans on using their series C funding to accelerate the development of its product pipeline by conducting multiple clinical trials in several therapeutic areas of interest to the company.

Timeline

People

Name
Role
LinkedIn

Allison Lawton

COO

Geoffrey von Maltzahn

Chief Innovation Officer

Mike Bonney

CEO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 14, 2020
BioSpace
Kaleido Biosciences, Inc., a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health announced the initiation of a controlled clinical study evaluating Microbiome Metabolic Therapy candidate KB109 added to Supportive Self-Care for outpatients who are positive for SARs-Cov-2 infection with mild-to-moderate COVID-19.
Research and Markets
Invalid Date
www.prnewswire.com:443
DUBLIN, Feb. 13, 2019 /PRNewswire/ -- The "5th Annual Translational Microbiome Conference - Industry" conference has been added to ResearchAndMarkets.com's...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.